TWD
BCAX

True Wealth Design’s Bicara Therapeutics BCAX Stock Holding History

True Wealth Design’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$683 Hold
23
– – ﹤0.01% 2101
2026
Q1 		$458 Hold
23
– – ﹤0.01% 2089
2025
Q4 		$388 Hold
23
– – ﹤0.01% 2030
2025
Q3 		$364 Hold
23
– – ﹤0.01% 2110
2025
Q2 		$214 Sell
23
-10
-30% -$119 ﹤0.01% 2053
2025
Q1 		$430 Buy
+33
New +$438 ﹤0.01% 1605

Other funds holding BCAX

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

True Wealth Design's BCAX Position: Q2 2026 in Review

True Wealth Design held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 23 shares worth $683. The position accounts for ﹤0.01% of the portfolio, ranked #2101.

True Wealth Design first reported a position in BCAX in Q1 2025 and has held it in 6 quarters since. 5 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • True Wealth Design held 23 shares of Bicara Therapeutics worth $683 as of Q2 2026.
  • True Wealth Design left its Bicara Therapeutics share count unchanged in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2101 holding.
  • True Wealth Design first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 5 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.